Sunesis Pharmaceuticals (SNSS)
Sunesis Pharmaceuticals Revenues
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
SNSS Revenues Range, Past 5 Years
| Minimum | 0.006M | Dec 2010 |
| Maximum | 4.00M | Mar 2011 |
| Average | 1.335M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these SNSS related companies
SNSS News
RBC Capital Upgrades Sunesis Pharmaceuticals Inc. (SNSS) to Outperform
May 29, 7:34AM Street Insider
May 29, 7:34AM Street Insider
Cup and Handle setup in SNSS...waiting for breakout... $SNSS http://chart.ly/gcfalem
about 10 days ago by cupandhandle69
about 10 days ago by cupandhandle69
$SNSS Looking bearish, last candle sticks on here. Have my eye on this now tho
about 13 days ago by newkidontheblock
about 13 days ago by newkidontheblock
Hey, my getoffurassanddosomething speech to $SNSS is working! up 26 cents in 2 days. saWEET!
about 15 days ago by Bleedblue
about 15 days ago by Bleedblue
$SNSS forms bullish "Symmetrical Continuation Triangle" chart pattern. http://stks.co/3qUo
about 15 days ago by RecogniaEvents
about 15 days ago by RecogniaEvents
$CYCC biotech-sure your not short this stock? $SNSS gone from 1.40-$2.90 while sh!tlacell gone from 66 pennies to 46 pennies-just saying...
about 16 days ago by oliveblakcok
about 16 days ago by oliveblakcok
$SNSS VS $CYCC marketcap 130M x 30M HMMM ? in same UK trial for AML when will $CYCC hit radars finaly? multibagger imo
about 16 days ago by biotech
about 16 days ago by biotech
$SNSS Mentioned more than normal on StockTwits - Currently at 8 x average daily social activity
about 16 days ago by TradeIdeasQuant
about 16 days ago by TradeIdeasQuant
Quant modell indicates a 2 - 1 chance for $SNSS not closing above 2.95 today. Now trading at 2.92 or +9.4%
about 16 days ago by TradeBot
about 16 days ago by TradeBot
RT @Jennja4REAL $SNSS has been on my watch. How did I miss that move. #DANG , i'm in since mid april, but yes what a shocker 2day! I LIKE!
about 16 days ago by Bleedblue
about 16 days ago by Bleedblue
Listen to $SNSS Q1 2012 earnings call - live at 11:00 AM, ondemand after - http://stks.co/3pes
about 16 days ago by earningscast
about 16 days ago by earningscast
Sunesis Pharmaceuticals Reports First Quarter 2012 Financial Results and Highlights
May 15, 7:00AM GlobeNewswire
May 15, 7:00AM GlobeNewswire
$PSTI will not only create a good return on my investment but has helped humanity as well. Hopefully $SNSS will do the same.
about 22 days ago by bluesfreak
about 22 days ago by bluesfreak
Sunesis to Host Conference Call on May 15th to Discuss First Quarter Financial Results and Recent Highlights
May 08, 7:00AM GlobeNewswire
May 08, 7:00AM GlobeNewswire
Sunesis Pharmaceuticals Receives European Orphan Drug Designation for Vosaroxin to Treat Acute Myeloid Leukemia
May 03, 7:00AM GlobeNewswire
May 03, 7:00AM GlobeNewswire
Cantor Fitzgerald Initiates Coverage on Sunesis Pharmaceuticals with Buy Rating, $6 PT
Apr 13, 10:41AM Benzinga
Apr 13, 10:41AM Benzinga
Sunesis to Present at the 19th Annual Future Leaders in the Biotech Industry Conference
Apr 13, 7:00AM GlobeNewswire
Apr 13, 7:00AM GlobeNewswire
Sunesis Pharmaceuticals (SNSS) Awarded $25 Million in From Royalty Pharma
Mar 29, 4:26PM Street Insider
Mar 29, 4:26PM Street Insider
Sunesis and Royalty Pharma Announce $25 Million Vosaroxin Royalty Agreement
Mar 29, 4:23PM GlobeNewswire
Mar 29, 4:23PM GlobeNewswire
Canaccord Genuity reiterates a 'Buy' on Sunesis Pharmaceuticals (SNSS); Attractive Risk/Reward Ahead of Results
Mar 15, 10:42AM Street Insider
Mar 15, 10:42AM Street Insider
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2011 Financial Results and Highlights
Mar 14, 7:00AM GlobeNewswire
Mar 14, 7:00AM GlobeNewswire
Sunesis to Host Conference Call on March 14th to Discuss Fourth Quarter and Full-Year 2011 Financial Results
Mar 08, 7:00AM GlobeNewswire
Mar 08, 7:00AM GlobeNewswire
UPDATE - Canaccord Genuity Initiates Coverage on Sunesis Pharmaceuticals (SNSS) with a Buy; Plan of Attack Against AML
Mar 06, 8:19AM Street Insider
Mar 06, 8:19AM Street Insider
Sunesis to Present at the Cowen and Company 32nd Annual Health Care Conference
Feb 29, 7:00AM GlobeNewswire
Feb 29, 7:00AM GlobeNewswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| SNSS | 2.92 | -0.09 | -2.99% | 140.93M |
| SNPS | 29.22 | -0.33 | -1.12% | 4.308B |
| SNP | 88.88 | -1.07 | -1.19% | 85.29B |
| SNN | 46.19 | -0.49 | -1.05% | 8.343B |
| SNMX | 2.27 | -0.04 | -1.73% | 91.87M |
| SNCR | 17.51 | +0.30 | +1.74% | 662.93M |
| SNAK | 6.31 | -0.06 | -0.94% | 115.74M |
| SNA | 59.66 | -0.59 | -0.98% | 3.510B |
| SN | 23.75 | -0.53 | -2.18% | 839.36M |
| SMTX | 3.18 | -0.08 | -2.45% | 51.21M |